Research & Education

The Dutch-Belgian NELSON lung cancer screening trial results are inferable for the general high-risk population.

Results of the NELSON lung cancer screening trial using low dose computed tomography (LDCT) can be used to predict the effect of population-based screening on the Dutch population even though there were slight differences in baseline characteristics of participants in the control arm versus eligible non-participants.

Not all EGFR mutations are the same when it comes to therapy for non-small cell lung cancer.

Certain rare epidermal growth factor receptor (EGFR) mutations are associated with tobacco smoking, worse prognosis and poor response to EGFR tyrosine kinase inhibitor (TKI) therapy compared to the more common “classical” EGFR mutations. However, as not all rare mutations are the same, testing and therapy may need to be evaluated for each individual mutation.

Testing for EGFR mutations and ALK rearrangements is cost-effective in non-small cell lung cancer.

Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.

A survey of the general population in France identifies knowledge gaps in the perception of lung cancer.

DENVER – A prospective nationwide survey on perceptions of lung cancer in the general population of France highlights a need for increased public education on the benefits of lung cancer screening, the good survival rates of early-stage disease and the improved outcomes with new therapeutic strategies, including targeted-therapies.

Targeted next-generation sequencing reveals a high number of genomic mutations in advanced malignant plural mesothelioma.

DENVER – Next generation sequencing in malignant pleural mesothelioma (MPM) tumors shows a complex mutational setting with a high number of genetic alterations in genes involved in DNA repair, cell survival and cell proliferation pathways. Increased accumulation of mutations correlates with early progression of the tumor and decreased survival.

IASLC Supports the CMS Formal Proposal to Pay For Lung Cancer Screening

DENVER – The International Association for the Study of Lung Cancer (IASLC) is pleased that the Centers for Medicare & Medicaid Services (CMS) made a draft proposal Monday to cover low-dose CT screening of patients at high risk for lung cancer.